us healthcare and life sciences conference
TRANSCRIPT
In association with
VENUE INFORMATIONMay 15, 2014 | New York Hilton Midtown NEW YORK
US HEALTHCARE AND LIFE SCIENCES CONFERENCE
SPEAKERS INCLUDE:
David CordaniPresident and CEOCigna
Omar Ishrak, PhDChairman and CEO Medtronic
Freda C. Lewis-Hall, MD Executive Vice President, Chief Medical Offi cerPfi zer
J. Craig Venter, PhD Founder, CEO and ChairmanJ. Craig Venter Institute
Luncheon sponsorLead sponsor
The third annual US Healthcare and Life Sciences Conference hosted by the Financial Times, in association with Deloitte, will take place on May 15, 2014 in New York.
As healthcare reforms in the US gain traction, stakeholders are recalibrating their roles and relationships across the healthcare value chain. Chaired by Andrew Ward, Pharmaceuticals Correspondent of the Financial Times, this full-day conference brings together the industry’s leading experts and commentators to explore how reforms are reshaping market access, and the way healthcare is consumed and paid for.
9:00am OPENING REMARKS FROM THE CHAIR
Andrew Ward, Pharmaceuticals Correspondent, Financial Times
9:05 am VIEW FROM THE TOP: CEO INTERVIEW
Sandra Peterson, Group Worldwide Chairman, Johnson & Johnson
9:30 am US HEALTHCARE REFORM: THE NEXT CHAPTER
As we prepare to enter the fourth year since the Accountable Care Act (ACA) was enacted, the reforms are gaining traction. Despite initial challenges, enrolment in the new health insurance exchanges is underway. Payers, providers and life insurance companies are experimenting with new pay-for-performance measures, and established and emerging players are realizing the potential for, and slowly building new businesses focused on bringing healthcare close to patient. In so doing, many of the stakeholders in the healthcare business are recalibrating relationships across the healthcare value chain. 2014 is a critical year in the reform process as the individual mandate kicks-in. As we cross this new threshold, what has been the impact of reform to date and the key learnings?
PROGRAMME
US HEALTHCARE AND LIFE SCIENCES CONFERENCE
• How is reform impacting the ‘ecosystem’ of the healthcare and life science industry and how are stakeholder strategies evolving to take advantage of reform? • How is reform reshaping market access?• How is reform changing the way patients consume healthcare? Are they seeing improvements in their care and access?
Drew Altman, PhD, President and CEO, Kaiser Family FoundationJohn Castellani, President and CEO, PhRMAKaren Ignagni, President and CEO, America’s Health Insurance Plans (AHIP)Stephen Rusckowski, President and CEO, Quest Diagnostics
10:30 am NETWORKING COFFEE BREAK
11:00 am KEYNOTE ADDRESS
Esther Dyson, Chairman, EDventure Holdings
11:25 am HEALTHCARE EVERYWHERE: EMBRACING THE MOBILE HEALTH OPPORTUNITY
Mobile healthcare, particularly when combined with other smart technologies including the cloud, social networking and the power of big data, has the potential to transform healthcare through reduced costs, extended access, changed behaviors and improved outcomes. While the reported benefi ts of mHealth are well known, however, many still do not know, or have been unable to capitalise on the potential and develop mobile strategies which move beyond marketing and applications to solutions and partnerships which can make a quantum impact across the continuum of care. How can the potential of mobile health be harnessed to make a real and tangible impact on health costs and transformation?
• What are the impediments and how can they be addressed? How is the legal, regulatory and reimbursement regime evolving to support the expansion of mobile health and to address concerns regarding privacy and security? • What are the business models for mHealth which will provide solid returns for those who take the investment risk? How are key issues including interoperability being resolved to enable actionable knowledge and insights from accrued mobile data and to achieve scalable benefi ts from mHealth through wider collaboration across the health care spectrum?
MODERATOR: Harry Greenspun, MD, Senior Advisor for Healthcare Transformation & Technoligy, Deloitte Center for Health Solutions
SESSION KEYNOTE: Freda C. Lewis-Hall, MD, Executive Vice President, Chief Medical Offi cer, Pfi zerTom Gentile, President & CEO, Healthcare Systems, GE HealthcareKerry McDermott, Senior Director, Healthcare Technology Policy, West Health Policy Center
12:25 pm CEO INSIGHTS Joe Herring, Chairman and CEO, Covance
12:45 pm LUNCHEON
LUNCHEON SPONSOR:
KEYNOTE ADDRESS: David Cordani, President and CEO, Cigna
2:15 pm KEYNOTE ADDRESS
Derek Yach, MB ChB, Executive Director, The Vitality Institute
2:40 pm VALUE-BASED CONTRACTING AND PAYMENTS – RISING TO THE CHALLENGE
Universality of access may be making headlines in the on-going debate on US healthcare reform but potentially the largest impact will come from the measures aimed at tackling the escalating cost and improving the quality of care. From Accountable Care Organizations and CER in the US to the UK’s value-based pricing, ’pay-for-performance’ reforms are making inroads and transforming healthcare around the globe. The goals of the new value system are clear but many uncertainties remain.
• What is the evidence to date from the ACO pilots and value based pricing models for life science currently in place? What are the prospects that new structures will lead to a sustainable and notable disruption in the quality and cost of care? • Will the benefi ts outweigh the costs and risks, and is the infrastructure ready to underpin the system? • What are the value metrics and incentive structures, and are current methodologies fair? Who decides? • How are new pay-for-performance measures impacting access for life science companies? How does the US experience compare to that in Europe and elsewhere?
SESSION KEYNOTE: Charles W. Sorenson, MD, President and CEO, Intermountain HealthcareJack Bailey, Senior Vice President, Policy, Payers and Vaccines, GlaxoSmithKlineTerry Hisey, Vice Chairman, US Life Sciences Leader, DeloitteDavid Wennberg, MD, CEO, Northern New England Accountable Care Collaborative (NNEACC)
3:40 pm NETWORKING COFFEE BREAK
4:00 pm CEO INSIGHTS
Omar Ishrak, PhD, Chairman and CEO, Medtronic
4:25 pm CLOSING KEYNOTE
J. Craig Venter, PhD, Founder, CEO and Chairman, J. Craig Venter Institute
4:55 pm CLOSING REMARKS FROM THE CHAIR
Andrew Ward, Pharmaceuticals Correspondent, Financial Times
5:05 pm END OF CONFERENCE
For the latest programme and speaker updates, visit
www.ft-live.com/USHC2014
WHO SHOULD ATTEND:
This event is for: CEOs, CFOs, CIOs, Chief Medical Offi cers, Chief Strategy Offi cers, Heads of R&D, Emerging Markets, Consumer Health, Government Relations, Pricing, Regulation, Market Access, etc. and other senior-level executives in the following sectors:
• Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies
• Medical Devices and Diagnostics• Investment (Fund Managers, Venture Capitalists, Private
Equity fi rms, Investment Bankers, IP Groups)• Legal Counsel• Healthcare IT (Patient records, data, mobile healthcare
applications, social media)• Regulation
SUPPORTING PARTNERS
HOW TO REGISTER
www.ft-live.com/ushc2014
New York Hilton Midtown1335 Avenue of the AmericasNew York, NY 10019
Phone: +1-212-586-7000
VENUE INFORMATION
INFORMATION
For registration, discounts and general attendance information:
Melissa Papasidero
+1 917-551-5106
For sponsorship enquiries:
Tim Powell
+1 917-551-5097
E
T
E
T
@FTLive #FTUSHC facebook.com/FinancialTimesLive on.ft.com/linkedin
SUMMIT PRICING
Rate Fee
Early rate II(expires Mar 28)
Standard Rate
Standard Registration $1395 $1695
Non-profit/Government $695 $795
US HEALTHCARE AND LIFE SCIENCES CONFERENCE